Molecular Partners Updates Pipeline As MP0712 Dosing Continues, NuMeRI Initiates Compassionate Care With 225Ac DLL3 Radio-DARPin, And MP0726 Imaging Targeted For Second Half Of 2026

Molecular Partners AG Sponsored ADR

Molecular Partners AG Sponsored ADR

MOLN

0.00
  • Phase 1/2a trial of MP0712, 212Pb-based DLL3-targeted Radio-DARPin co-developed with Orano Med: Dosing ongoing in first patients; initial data anticipated within the coming months, comprehensive efficacy data expected in 2027
  • Additional compassionate care work now initiated by the Nuclear Medicine Research Institute in South Africa utilizing 225Ac-loaded DLL3 Radio-DARPin, highlighting the versatility of DARPins as isotope agnostic vectors
  • FIH imaging for MP0726, Radio-DARPin targeting MSLN, planned to start in H2 2026
  • New target nomination in H2 2026, with two INDs planned in 2027 
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.